The concept, the mechanism and the real status of stem cell injection for kidney disease
Quick answer
Stem cell treatment for kidney disease means infusing mesenchymal stem cells (MSCs) with the aim of reducing inflammation and fibrosis in renal tissue, slowing decline and supporting functional kidney regeneration. In Korea the best-known example is EHL Bio's KDSTEM inj., which uses the patient's own urine-derived stem cells. It remains investigational, not standard care.
Chronic kidney disease differs from acute injury: the damage accumulates silently, and tissue replaced by fibrosis never functions again. The goal of kidney regeneration is therefore not to grow a new kidney but to preserve the nephrons still working. That is the correct expectation to hold before considering any cell therapy.
The mechanism researchers focus on is the paracrine effect: MSCs secrete signalling molecules, exosomes and growth factors that calm inflammatory and fibrosis-producing cells, rather than engrafting into kidney tissue themselves. That explains why most protocols use repeat dosing rather than a single infusion.
In Korea, EHL Bio developed KDSTEM inj. using autologous urine-derived MSCs that express Klotho, a protein abundant in healthy kidneys and depleted in CKD. The cells are expanded in a GMP facility and given as repeat intravenous infusions. The programme sits in preclinical and early clinical development.
The first practical step for a patient is knowing their own numbers: eGFR, creatinine, urine albumin-to-creatinine ratio and the underlying cause of the kidney disease. Every consultation, in Thailand or Korea, starts from those figures, and they are what later shows whether anything actually worked.
There is no evidence of a cure. Research targets slower decline and less inflammation, not restoration of a normal kidney.
Most work focuses on patients with functioning nephrons left — stages 3 to 4 rather than stage 5 on renal replacement therapy.
No, and you should not. ACEi/ARB, SGLT2 inhibitors and blood pressure and glucose control remain the backbone of kidney care.
Typically eGFR and proteinuria are reviewed at three and six months. Feeling better in the first week is not a result.
The main risks are infusion reactions, infection and substandard cell products, so it should only happen in facilities with GMP processing and formal follow-up.
To receive a Korea-developed therapy, yes. Baseline testing and ongoing care can still be done in Thailand with your own nephrologist.
5 points • reviewed 2026-09-02
Reviewed and last updated: 2026-09-02
5 sources • every claim is traceable
https://www.ehlbio.co.kr
https://www.mfds.go.kr/eng/index.do
https://www.mohw.go.kr/eng/
https://pubmed.ncbi.nlm.nih.gov/
https://www.medicalkorea.or.kr/
Last updated: 2026-09-02 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categories